Sugi Predict

Sugi Predict / Compounds / SCHEMBL5312359

SCHEMBL5312359

SCHEMBL5312359

Cn1ccc2cc(F)ccc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.43
▸ CDK4 P11802 3/20 0.41
▸ CCND1 P24385 3/20 0.41
▸ CCNE2 O96020 2/20 0.41
▸ CCNE1 P24864 2/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ BRD4 O60885 5/20 0.41
▸ BRD9 Q9H8M2 2/20 0.41
▸ TAF1 P21675 1/20 0.41
▸ BRPF1 P55201 1/20 0.41
▸ CREBBP Q92793 1/20 0.41
▸ CECR2 Q9BXF3 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ HTR6 P50406 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ FEN1 P39748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29809286 1.00 ALOX5 (0.43) ALOX5CDK4CCND1CCNE2CCNE1
SCHEMBL9919030 0.85 CDK4 (0.43) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL30617770 0.79 BRD4 (0.42) ALOX5CDK4CCND1CCNE2CCNE1
SCHEMBL7601676 0.79 MEN1 (0.49) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL12177181 0.79 BRD9 (0.42) ALOX5CDK2BRD4BRD9TAF1
SCHEMBL29809554 0.79 MEN1 (0.49) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL23346719 0.78 PRKCI (0.56) CDK2BRD4BRD9TAF1BRPF1
SCHEMBL582859 0.78 CCNE2 (0.41) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL9919031 0.78 BRD9 (0.41) BRD4BRD9TAF1BRPF1CREBBP
SCHEMBL29809118 0.78 CCNE2 (0.41) CDK4CCND1CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
EP-3640241-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-28 — — EP disclosed
CN-108558889-B Bromodomain inhibitors 赛尔基因昆蒂赛尔研究公司 2021-11-05 — — CN disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2007053352-A2 PYRROLOQUINOLINONE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2007-05-10 — — WO disclosed
US-20070099911-A1 Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALOX5 4209/4885CDK4 305/4885CCND1 1172/4885
US-20070099911-A1 Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C ALOX5 461/4885CDK4 1947/4885CCND1 3931/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALOX5 4209/4885CDK4 305/4885CCND1 1172/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALOX5 4209/4885CDK4 305/4885CCND1 1172/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 ALOX5 4209/4885CDK4 305/4885CCND1 1172/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 ALOX5 4209/4885CDK4 305/4885CCND1 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.